Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Gilead Sciences

Pharmaceutical executives challenge Texas court’s abortion pill ruling

Gilead Sciences and Pfizer join amicus brief

The Independent UK

2 Biotech Stocks to Buy Hand Over Fist in March

The biotech industry is expected to expand rapidly, driven by significant advancements and government initiatives. Furthermore, this sector tends to be relatively defensive and holds up relatively well during downturns. So, fundamentally sound biotech stocks Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) might be ideal buys now. Keep reading.

StockNews.com

3 Dividend Paying Stocks to Buy in March

With the stock market anticipated to stay volatile due to persistent concerns about high inflation, interest rate hikes, and a recession, fundamentally solid dividend stocks Gilead Sciences (GILD), CVS Health (CVS), and Altria (MO) might be great buys for a steady income stream. Keep reading.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

It’s Time to Buy Up These 3 Growth Stocks In 2023

While higher rates have hurt growth stocks last year, 2023 could be the year of growth stocks gaining momentum. Amid rising optimism, investors could consider buying fundamentally strong growth stocks Gilead Sciences (GILD), Jazz (JAZZ), and Masonite International (DOOR) this year. Keep reading.

StockNews.com

2 Biotech Stocks to Buy and 1 to Avoid Like the Plague

The biotech industry is expected to witness solid growth driven by growing government initiatives and increasing demand across several sectors. While we think fundamentally sound biotech stocks Gilead Sciences (GILD) and United Therapeutics (UTHR) could be solid buys this year, Bionano Genomics (BNGO) could be best avoided considering its fundamental…

StockNews.com

3 Safe High-Dividend Stocks to Buy Right Now

While inflation pressures seem to be cooling, the Fed is expected to continue with its rate hikes, raising the chances of a recession this year. Hence, high-dividend stocks AbbVie (ABBV), Gilead Sciences (GILD), and Marine Products (MPX) might be solid buys for steady income amid current uncertainties. Keep reading.

StockNews.com

Up More than 19% In 2022, Is Gilead Sciences Still a Buy?

Gilead Sciences (GILD) beat revenue and earnings estimates in the previous quarter and upgraded its guidance for fiscal 2022. Having risen more than 19% year-to-date, is GILD still a buy? Read on to learn our view.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Monkeypox: latest data reveals how the virus has affected women and non-binary people

Since May 2022, a global outbreak of human monkeypox infections has been reported in over 78,000 people. So far, infections have overwhelmingly occurred in sexually active men who have sex with men.

The Conversation

Is Gilead Sciences Still a Buy Post COVID-19?

Gilead Sciences’ (GILD) popular covid product Veklury (Remdisivir) witnessed declining sales in the post-pandemic era. However, the company’s top line, excluding Veklury, has seen steady growth. Moreover, despite ongoing market volatility, the stock has registered stable gains. So, let’s find out if GILD is still a buy in the post-covid…

StockNews.com

Gilead Sciences Unusual Options Activity

Someone with a lot of money to spend has taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022

Upgrades

Benzinga

Check Out What Whales Are Doing With GILD

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2022

Upgrades

Benzinga

U.S. sends experimental antibody, antiviral drug to Uganda for Ebola outbreak

The United States sent Gilead Sciences' remdesivir and Mapp Biopharmaceutical Inc's experimental Ebola antibody drug MBP134 to Uganda last week to help safeguard healthcare workers responding to an outbreak that has infected 60 people and killed 44, U.S. government sources told Reuters.

Reuters

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Gilead Sciences Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

StockNews.com

3 Biotech Stocks to Buy for Q4 and 1 to Avoid

Favorable federal investments are anticipated to fuel further expansion in the biotech industry. Given the sector’s good prospects, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys. However, fundamentally weak stock Intra-Cellular Therapies (ITCI) might be best avoided. Read on….

Benzinga

What Are Whales Doing With Gilead Sciences

A whale with a lot of money to spend has taken a noticeably bullish stance on Gilead Sciences. Looking at options history for Gilead Sciences (NASDAQ:GILD) we detected 17 strange trades.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2022

Upgrades

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

StockNews.com

1 Biotech Stock Investors Will Want to Buy This Week

Gilead Sciences (GILD), a biopharmaceutical company, reported strong demand across its HIV portfolio and raised its full-year guidance. Given the company’s robust profitability and discounted valuation, we think it could be wise to buy the stock now. Read on….

Reuters

Drugmaker Gilead to help fund monkeypox education for LGBTQ+ groups

Drugmaker Gilead Sciences plans to announce on Tuesday that it will provide up to $5 million in grants to help a coalition of LGBTQ+ and human rights advocacy groups craft public health responses to monkeypox outbreaks, the company said.

The Conversation

Direct-acting antivirals can cure hepatitis C and prisons are now leading efforts to eliminate the virus

While most medical attention has been on COVID, work has been underway to eliminate another viral disease, hepatitis C.

Benzinga

Recap Of Friday's Biotech Catalysts - End Of The Day Summary

Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…

Benzinga

Gilead Sciences Whale Trades For July 14

Benzinga

Gilead Again Seeks HIV Drug Approval From FDA After Addressing Vial Compatibility Issues

Gilead Sciences (NASDAQ: GILD) resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection.

1 2 3 4 5

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

Matthew Kacsmaryk

224 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Advanced Micro Devices

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.